ArticleMolecular neurobiology2025
Upregulation of PD-1 on Peripheral T cells Subsets is Associated with Parkinson's Disease.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multidimensional Characterization of Parkinson's Disease Subtypes Through Motor Neuron Excitability and Peripheral Immune Dynamics: Insights from F-Wave Modulation Metrics.Diagnostics (Basel, Switzerland) · 2025Article
- Research progress on natural products in regulating the gut microbiota in Parkinson's disease.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease, and previous research has shown that T cell-mediated immunity plays a key role in PD pathology. Programmed cell death protein 1 (PD-1) is a type I transmembrane protein that inhibits T lymphocyte inflammatory activity, and PD-1 deletion can reduce dopamine levels in mouse brains. However, the clinical status of PD-1 in PD patients remains obscure. To understand the clinical role of PD-1, flow cytometry (FCM) was used to assess peripheral blood mononuclear cells (PBMCs) from 16 patients with Parkinson's disease and 16 controls in our study. With respect to PD-1 expression on peripheral T lymphocytes, we found a statistically greater proportion of PD-1 on CD8
Indexed as
Identifiers
40536591What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.